The Claim
In adults with prior percutaneous coronary intervention but no prior myocardial infarction and LDL cholesterol ≥90 mg/dL, treatment with evolocumab for a median of 4.6 years reduces the risk of myocardial infarction by 50% compared to placebo, with a 5-year event rate of 3.0% versus 6.1%.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Among adults who had a heart procedure but never had a heart attack and have high LDL cholesterol, taking evolocumab for about 4.6 years lowers the chance of having a heart attack from 6.1% to 3.0% over five years compared to not taking it.
See the scientific wording
In adults with prior percutaneous coronary intervention but no prior myocardial infarction and LDL cholesterol ≥90 mg/dL, treatment with evolocumab for a median of 4.6 years reduces the risk of myocardial infarction by 50% compared to placebo, with a 5-year event rate of 3.0% versus 6.1%.
A drug blocks a protein that normally destroys liver receptors that remove bad cholesterol from the blood. With more receptors available, cholesterol levels drop sharply. Less cholesterol builds up in artery walls, making plaques less inflamed and more stable. Stable plaques do not rupture, so blood clots do not form and block heart arteries, preventing heart attacks.
What the research says
1 studyFor people who had a heart stent but never had a heart attack and have very high cholesterol, taking evolocumab for about five years cut their chance of having a heart attack in half compared to those who didn’t take it.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.